The structuring body : a critical study in the description & explanation of perceptual experience

The aims of the dissertation are to find the right description of the structure of perceptual experience and to explore the ways in which the structure of the body might serve to explain it. In the first two parts, I articulate and defend the claim that perceptual experience seems direct and the claim that its objects seem real. I defend these claims as integral parts of a coherent metaphysically neutral conception of perceptual experience. Sense-datum theorists, certain influential perceptual psychologists, and early modern philosophers (most notably Berkeley) all disputed the claim that perceptual experience seems direct. In Part I, I argue that the grounds on which they did so were poor. The aim is then, in Part II, to give a proper appreciation of the distinctive intentionality of perceptual experience whilst remaining metaphysically neutral. I do so by drawing on the early work of Edmund Husserl, providing a characterisation of the perceptual experience of objects as real, qua mind-independent particulars. In Part III, I explore two possible explanations of the structure characterising the intentionality of perceptual experience, both of which accord a distinctive explanatory role to the body. On one account, perceptual experience is structured by an implicit pre-reflective consciousness of oneself as a body engaged in perceptual activity. An alternative account makes no appeal to the metaphysically laden concept of a bodily self. It seeks to explain the structure of perceptual experience by appeal to anticipation of the structural constraints of the body. I develop this alternative by highlighting the conceptual and empirical basis for the idea that a first-order structural affordance relation holds between a bodily agent and certain properties of its body. I then close with a discussion of the shared background assumptions that ought to inform disputes over whether the body itself (in addition to its representation) ought to serve as an explanans in such an account.

Structural patterns for document engineering: from an empirical bottom-up analysis to an ontological theory

This thesis aims at investigating a new approach to document analysis based on the idea of structural patterns in XML vocabularies. My work is founded on the belief that authors do naturally converge to a reasonable use of markup languages and that extreme, yet valid instances are rare and limited. Actual documents, therefore, may be used to derive classes of elements (patterns) persisting across documents and distilling the conceptualization of the documents and their components, and may give ground for automatic tools and services that rely on no background information (such as schemas) at all. The central part of my work consists in introducing from the ground up a formal theory of eight structural patterns (with three sub-patterns) that are able to express the logical organization of any XML document, and verifying their identifiability in a number of different vocabularies. This model is characterized by and validated against three main dimensions: terseness (i.e. the ability to represent the structure of a document with a small number of objects and composition rules), coverage (i.e. the ability to capture any possible situation in any document) and expressiveness (i.e. the ability to make explicit the semantics of structures, relations and dependencies). An algorithm for the automatic recognition of structural patterns is then presented, together with an evaluation of the results of a test performed on a set of more than 1100 documents from eight very different vocabularies. This language-independent analysis confirms the ability of patterns to capture and summarize the guidelines used by the authors in their everyday practice. Finally, I present some systems that work directly on the pattern-based representation of documents. The ability of these tools to cover very different situations and contexts confirms the effectiveness of the model.

Charakterisierung von optischen Partikelspektrometern und in-situ Messungen zur Mikrophysik der polaren Stratosphärenwolken

Polare Stratosphärenwolken (PSC), die unterhalb einer Temperatur von etwa -78 °C in polaren Regionen auftreten, üben einen starken Einfluss auf die stratosphärische Ozonschicht aus. Dieser Einfluss erfolgt größtenteils über heterogene chemische Reaktionen, die auf den Oberflächen von Wolkenpartikeln stattfinden. Chemische Reaktionen die dabei ablaufen sind eine Voraussetzung für den späteren Ozonabbau. Des Weiteren verändert die Sedimentation der Wolkenpartikel die chemische Zusammensetzung bzw. die vertikale Verteilung der Spurengase in der Stratosphäre. Für die Ozonchemie spielt dabei die Beseitigung von reaktivem Stickstoff durch Sedimentation Salpetersäure-haltiger Wolkenpartikeln (Denitrifizierung) eine wichtige Rolle. Durch gleichen Sedimentationsprozess von PSC Elementen wird der Stratosphäre des weiteren Wasserdampf entzogen (Dehydrierung). Beide Prozesse begünstigen einen länger andauernden stratosphärischen Ozonabbau im polaren Frühling.rnGerade im Hinblick auf die Denitrifikation durch Sedimentation größerer PSC-Partikel werden in dieser Arbeit neue Resultate von in-situ Messungen vorgestellt, die im Rahmen der RECONCILE-Kampagne im Winter des Jahres 2010 an Bord des Höhenforschungs-Flugzeugs M-55 Geophysica durchgeführt wurden. Dabei wurden in fünf Flügen Partikelgrößenverteilungen in einem Größenbereich zwischen 0,5 und 35 µm mittels auf der Lichtstreuung basierender Wolkenpartikel-Spektrometer gemessen. Da polare Stratosphärenwolken in Höhen zwischen 17 und 30 km auftreten, sind in-situ Messungen vergleichsweise selten, so dass noch einige offene Fragen bestehen bleiben. Gerade Partikel mit optischen Durchmessern von bis zu 35µm, die während der neuen Messungen detektiert wurden, müssen mit theoretischen Einschränkungen in Einklang gebracht werden. Die Größe der Partikel wird dabei durch die Verfügbarkeit der beteiligten Spurenstoffe (Wasserdampf und Salpetersäure), die Sedimentationsgeschwindigkeit, Zeit zum Anwachsen und von der Umgebungstemperatur begrenzt. Diese Faktoren werden in der vorliegenden Arbeit diskutiert. Aus dem gemessenen Partikelvolumen wird beispielsweise unter der Annahme der NAT-Zusammensetzung (Nitric Acid Trihydrate) die äquivalente Konzentration des HNO 3 der Gasphase berechnet. Im Ergebnis wird die verfügbare Konzentration von Salpetersäure der Stratosphäre überschritten. Anschließend werden Hypothesen diskutiert, wodurch das gemessene Partikelvolumen überschätzt worden sein könnte, was z.B. im Fall einer starken Asphärizität der Partikel möglich wäre. Weiterhin wurde eine Partikelmode unterhalb von 2-3µm im Durchmesser aufgrund des Temperaturverhaltens als STS (Supercooled Ternary Solution droplets) identifiziert.rnUm die Konzentration der Wolkenpartikel anhand der Messung möglichst genau berechnen zu können, muss das Messvolumen bzw. die effektive Messfläche der Instrumente bekannt sein. Zum Vermessen dieser Messfläche wurde ein Tröpfchengenerator aufgebaut und zum Kalibrieren von drei Instrumenten benutzt. Die Kalibration mittels des Tröpfchengenerators konzentrierte sich auf die Cloud Combination Probe (CCP). Neben der Messfläche und der Größenbestimmung der Partikel werden in der Arbeit unter Zuhilfenahme von Messungen in troposphärischen Wolken und an einer Wolkensimulationskammer auch weitere Fehlerquellen der Messung untersucht. Dazu wurde unter anderem die statistische Betrachtung von Intervallzeiten einzelner Messereignisse, die in neueren Sonden aufgezeichnet werden, herangezogen. Letzteres ermöglicht es, Messartefakte wie Rauschen, Koinzidenzfehler oder „Shattering“ zu identifizieren.rn

L'evoluzione dei sistemi wireless verso il 5g

Sintetizzare le caratteristiche dei sistemi wireless fino al 4G ed evidenziare le innovazioni che verranno introdotte dai sistemi 5G

Ideazione di sistemi distribuiti collaborativi basati realta aumentata mobile: un caso di studio, con approfondimento relativo al livello delle comunicazioni

Il grande sviluppo a cui stiamo assistendo negli ultimi anni nell'ambito delle tecnologie mobile e del wearable computing apre le porte a scenari innovativi e interessanti per quanto riguarda sistemi distribuiti collaborativi. Le persone possono sempre più facilmente cooperare e scambiarsi informazioni grazie a queste nuove tecnologie e si può pensare allo sviluppo di sistemi che permettano forme molto avanzate di collaborazione facendo leva sull'aspetto hands-free, ovvero sulla possibilità di utilizzare dispositivi che liberino le mani, come i moderni smart-glasses. Per lo sviluppo di tali sistemi è necessario però studiare nuove tecniche e architetture, in quanto gli strumenti ad oggi a disposizione a supporto della realtà aumentata non sembrano essere del tutto adeguati per tale scopo. Infatti piattaforme come Wikitude o Layar, seppure offrano potenti tecniche di riconoscimento di markers e immagini e di rendering, non offrono quella dinamicità fondamentale per un sistema distribuito collaborativo. Questo scritto ha lo scopo di esplorare questi aspetti mediante l'ideazione, l'analisi, la progettazione e la prototipazione di un semplice caso di studio ispirato a sistemi collaborativi distribuiti basati su realtà aumentata. In particolare in questo lavoro si porrà l'attenzione sul livello delle comunicazioni e delle infrastrutture di rete.

Drug hypersensitivity reactions involving skin

Immune reactions to drugs can cause a variety of diseases involving the skin, liver, kidney, lungs, and other organs. Beside immediate, IgE-mediated reactions of varying degrees (urticaria to anaphylactic shock), many drug hypersensitivity reactions appear delayed, namely hours to days after starting drug treatment, showing a variety of clinical manifestations from solely skin involvement to fulminant systemic diseases which may be fatal. Immunohistochemical and functional studies of drug-specific T cells in patients with delayed reactions confirmed a predominant role for T cells in the onset and maintenance of immune-mediated delayed drug hypersensitivity reactions (type IV reactions). In these reactions, drug-specific CD4+ and CD8+ T cells are stimulated by drugs through their T cell receptors (TCR). Drugs can stimulate T cells in two ways: they can act as haptens and bind covalently to larger protein structures (hapten-carrier model), inducing a specific immune response. In addition, they may accidentally bind in a labile, noncovalent way to a particular TCR of the whole TCR repertoire and possibly also major histocompatibility complex (MHC)-molecules - similar to their pharmacologic action. This seems to be sufficient to reactivate certain, probably in vivo preactivated T cells, if an additional interaction of the drug-stimulated TCR with MHC molecules occurs. The mechanism was named pharmacological interaction of a drug with (immune) receptor and thus termed the p-i concept. This new concept may explain the frequent skin symptoms in drug hypersensitivity to oral or parenteral drugs. Furthermore, the various clinical manifestations of T cell-mediated drug hypersensitivity may be explained by distinct T cell functions leading to different clinical phenotypes. These data allowed a subclassification of the delayed hypersensitivity reactions (type IV) into T cell reactions which, by releasing certain cytokines and chemokines, preferentially activate and recruit monocytes (type IVa), eosinophils (type IVb), or neutrophils (type IVd).

Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity

In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long-lasting antibiotic treatments. For the clinician, the question arises whether these symptoms are due to cross-reactivity, are due to a new sensitization or are a reflection of a multiple drug hypersensitivity syndrome. Based on the p-i concept (pharmacological interaction with immune receptors), we propose that the efficient stimulation of T cells by a drug is the sum of drug-T-cell receptor affinity and readiness of the T cell to react, and therefore not constant. It heavily depends on the state of underlying immune activation. Consequently, drug hypersensitivity diseases, which go along with massive immune stimulations and often high serum cytokine values, are themselves risk factors for further drug hypersensitivity. The immune stimulation during drug hypersensitivity may, similar to generalized virus infections, lower the threshold of T-cell reactivity to drugs and cause rapid appearance of drug hypersensitivity symptoms to the second drug. We call the second hypersensitivity reaction a "flare-up" reaction; this is clinically important, as in most cases the second drug may be tolerated again, if the cofactors are missing. Moreover, the second treatment is often too short to cause a relevant sensitization.

Immune pathomechanism of drug hypersensitivity reactions

Drug hypersensitivity research has progressed enormously in recent years, and a greater understanding of mechanisms has contributed to improved drug safety. Progress has been made in genetics, enabling personalized medicine for certain drugs, and in understanding drug interactions with the immune system. In a recent meeting in Rome, the clinical, chemical, pharmacologic, immunologic, and genetic aspects of drug hypersensitivity were discussed, and certain aspects are briefly summarized here. Small chemicals, including drugs, can induce immune reactions by binding as a hapten to a carrier protein. Park (Liverpool, England) demonstrated (1) that drug haptens bind to protein in patients in a highly restricted manner and (2) that irreversibly modified carrier proteins are able to stimulate CD4(+) and CD8(+) T cells from hypersensitive patients. Drug haptens might also stimulate cells of the innate immune system, in particular dendritic cells, and thus give rise to a complex and complete immune reaction. Many drugs do not have hapten-like characteristics but might gain them on metabolism (so-called prohaptens). The group of Naisbitt found that the stimulation of dendritic cells and T cells can occur as a consequence of the transformation of a prohapten to a hapten in antigen-presenting cells and as such explain the immune-stimulatory capacity of prohaptens. The striking association between HLA-B alleles and the development of certain drug reactions was discussed in detail. Mallal (Perth, Australia) elegantly described a highly restricted HLA-B∗5701-specific T-cell response in abacavir-hypersensitive patients and healthy volunteers expressing HLA-B∗5701 but not closely related alleles. Expression of HLA-B∗1502 is a marker known to be necessary but not sufficient to predict carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han Chinese. The group of Chen and Hong (Taiwan) described the possible "missing link" because they showed that the presence of certain T-cell receptor (TCR) clonotypes was necessary to elicit T-cell responses to carbamazepine. The role of TCRs in drug binding was also emphasized by Pichler (Bern, Switzerland). Following up on their "pharmacological interactions of drugs with immune receptors" concept (p-i concept), namely that drugs can bind directly to TCRs, MHC molecules, or both and thereby stimulate T cells, they looked for drug-binding sites for the drug sulfamethoxazole in drug-specific TCRs: modeling revealed up to 7 binding sites on the CDR3 and CDR2 regions of TCR Vα and Vβ. Among many other presentations, the important role of regulatory T cells in drug hypersensitivity was addressed.

Etiology and pathogenesis of adverse drug reactions

In clinical routine, adverse drug reactions (ADR) are common, and they should be included in the differential diagnosis in all patients undergoing drug treatment. Only part of those ADR are immune-mediated hypersensitivity reactions and thus true drug allergies. Far more common are non-immune-mediated ADR, e.g. due to the pharmacological properties of the drug or to the individual predisposition of the patient (enzymopathies, cytokine dysbalance, mast cell hyperreactivity). In true drug allergiesT cell- and immunoglobulin E (lgE)-mediated reactions dominate the clinical presentation. T cell-mediated ADR usually have a delayed appearance and include skin eruptions in most cases. Nevertheless, it should not be forgotten that they may involve systemic T cell activation and thus take a severe, sometimes lethal turn. Clinical danger signs are involvement of mucosal surfaces, blistering within the exanthematous skin areas and systemic symptoms, e.g. fever or malaise. Drug presentation via antigen-presenting cells to T cells can either involve the classical pathway of haptenization of endogenous proteins or be directly mediated via noncovalent binding to immune receptors (MHC molecules or T cell receptors), the so-called p-i concept. Flare-up reactions during the acute phase of T cell-mediated ADR should not be mistaken for true drug allergies, as they only occur in the setting of a highly activated T cell pool. IgE-mediated ADR are less frequent and involve mast cells and/or basophils as peripheral effector cells. Recent data suggest that certain patients with drug allergy have a preexistent sensitization although they have never been exposed to the culprit drug, probably due to cross-reactivity. Thus, allergic drug reactions on first encounter are possible. In general, the extent of cross-reactivity is higher in IgE-compared to T cell-mediated ADR. Based on a specific ethnic background and only for severe T cell-mediated ADR to certain drugs, a strong HLA association has been established recently.

Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA

Recent publications have shown that certain human leukocyte antigen (HLA) alleles are strongly associated with hypersensitivity to particular drugs. As HLA molecules are a critical element in T-cell stimulation, it is no surprise that particular HLA alleles have a direct functional role in the pathogenesis of drug hypersensitivity. In this context, a direct interaction of the relevant drug with HLA molecules as described by the p-i concept appears to be more relevant than presentation of hapten-modified peptides. In some HLA-associated drug hypersensitivity reactions, the presence of a risk allele is a necessary but incomplete factor for disease development. In carbamazepine and HLA-B*15:02, certain T-cell receptor (TCR) repertoires are required for immune activation. This additional requirement may be one of the 'missing links' in explaining why most individuals carrying this allele can tolerate the drug. In contrast, abacavir generates polyclonal T-cell response by interacting specifically with HLA-B*57:01 molecules. T cell stimulation may be due to presentation of abacavir or of altered peptides. While the presence of HLA-B*58:01 allele substantially increases the risk of allopurinol hypersensitivity, it is not an absolute requirement, suggesting that other factors also play an important role. In summary, drug hypersensitivity is the end result of a drug interaction with certain HLA molecules and TCRs, the sum of which determines whether the ensuing immune response is going to be harmful or not.

Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds

In the context of drug hypersensitivity, our group has recently proposed a new model based on the structural features of drugs (pharmacological interaction with immune receptors; p-i concept) to explain their recognition by T cells. According to this concept, even chemically inert drugs can stimulate T cells because certain drugs interact in a direct way with T-cell receptors (TCR) and possibly major histocompatibility complex molecules without the need for metabolism and covalent binding to a carrier. In this study, we investigated whether mouse T-cell hybridomas transfected with drug-specific human TCR can be used as an alternative to drug-specific T-cell clones (TCC). Indeed, they behaved like TCC and, in accordance with the p-i concept, the TCR recognize their specific drugs in a direct, processing-independent, and dose-dependent way. The presence of antigen-presenting cells was a prerequisite for interleukin-2 production by the TCR-transfected cells. The analysis of cross-reactivity confirmed the fine specificity of the TCR and also showed that TCR transfectants might provide a tool to evaluate the potential of new drugs to cause hypersensitivity due to cross-reactivity. Recombining the alpha- and beta-chains of sulfanilamide- and quinolone-specific TCR abrogated drug reactivity, suggesting that both original alpha- and beta-chains were involved in drug binding. The TCR-transfected hybridoma system showed that the recognition of two important classes of drugs (sulfanilamides and quinolones) by TCR occurred according to the p-i concept and provides an interesting tool to study drug-TCR interactions and their biological consequences and to evaluate the cross-reactivity potential of new drugs of the same class.

Drug hypersensitivity

Drug hypersensitivity represents an immune-mediated reaction to a drug. Although several drug hypersensitivity reactions are confined to the skin and rather mild, some may be life threatening and also involve further organs such as liver, kidney and bone marrow. The exact pathogenesis of many drug hypersensitivity reactions is still obscure. In this review the concepts on how small molecular drugs can activate the immune system are discussed and the hapten, prohapten and p-i concept are explained. Furthermore, the classification of drug hypersensitivity reactions and some common and severe clinical manifestations of drug-induced T cell mediated reactions are presented.

Identification and quantification of phytochelatins in roots of rice to long-term exposure: evidence of individual role on arsenic accumulation and translocation

Rice has the predilection to take up arsenic in the form of methylated arsenic (o-As) and inorganic arsenic species (i-As). Plants defend themselves using i-As efflux systems and the production of phytochelatins (PCs) to complex i-As. Our study focused on the identification and quantification of phytochelatins by HPLC-ICP-MS/ESI-MS, relating them to the several variables linked to As exposure. GSH, 11 PCs, and As–PC complexes from the roots of six rice cultivars (Italica Carolina, Dom Sofid, 9524, Kitrana 508, YRL-1, and Lemont) exposed to low and high levels of i-As were compared with total, i-As, and o-As in roots, shoots, and grains. Only Dom Sofid, Kitrana 508, and 9524 were found to produce higher levels of PCs even when exposed to low levels of As. PCs were only correlated to i-As in the roots (r=0.884, P <0.001). However, significant negative correlations to As transfer factors (TF) roots–grains (r= –0.739, P <0.05) and shoots–grains (r= –0.541, P <0.05), suggested that these peptides help in trapping i-As but not o-As in the roots, reducing grains’ i-As. Italica Carolina reduced i-As in grains after high exposure, where some specific PCs had a special role in this reduction. In Lemont, exposure to elevated levels of i-As did not result in higher i-As levels in the grains and there were no significant increases in PCs or thiols. Finally, the high production of PCs in Kitrana 508 and Dom Sofid in response to high As treatment did not relate to a reduction of i-As in grains, suggesting that other mechanisms such as As–PC release and transport seems to be important in determining grain As in these cultivars.

Brain damage and addictive behavior: a neuropsychological and electroencephalogram investigation with pathologic gamblers.

BACKGROUND Gambling is a form of nonsubstance addiction classified as an impulse control disorder. Pathologic gamblers are considered healthy with respect to their cognitive status. Lesions of the frontolimbic systems, mostly of the right hemisphere, are associated with addictive behavior. Because gamblers are not regarded as "brain-lesioned" and gambling is nontoxic, gambling is a model to test whether addicted "healthy" people are relatively impaired in frontolimbic neuropsychological functions. METHODS Twenty-one nonsubstance dependent gamblers and nineteen healthy subjects underwent a behavioral neurologic interview centered on incidence, origin, and symptoms of possible brain damage, a neuropsychological examination, and an electroencephalogram. RESULTS Seventeen gamblers (81%) had a positive medical history for brain damage (mainly traumatic head injury, pre- or perinatal complications). The gamblers, compared with the controls, were significantly more impaired in concentration, memory, and executive functions, and evidenced a higher prevalence of non-right-handedness (43%) and, non-left-hemisphere language dominance (52%). Electroencephalogram (EEG) revealed dysfunctional activity in 65% of the gamblers, compared with 26% of controls. CONCLUSIONS This study shows that the "healthy" gamblers are indeed brain-damaged. Compared with a matched control population, pathologic gamblers evidenced more brain injuries, more fronto-temporo-limbic neuropsychological dysfunctions and more EEG abnormalities. The authors thus conjecture that addictive gambling may be a consequence of brain damage, especially of the frontolimbic systems, a finding that may well have medicolegal consequences.

Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01

Allopurinol (ALP) hypersensitivity is a major cause of severe cutaneous adverse reactions and is strongly associated with the HLA-B*58:01 allele. However, it can occur in the absence of this allele with identical clinical manifestations. The immune mechanism of ALP-induced severe cutaneous adverse reactions is poorly understood, and the T cell-reactivity pattern in patients with or without the HLA-B*58:01 allele is not known. To understand the interactions among the drug, HLA, and TCR, we generated T cell lines that react to ALP or its metabolite oxypurinol (OXP) from HLA-B*58:01(+) and HLA-B*58:01(-) donors and assessed their reactivity. ALP/OXP-specific T cells reacted immediately to the addition of the drugs and bypassed intracellular Ag processing, which is consistent with the "pharmacological interaction with immune receptors" (p-i) concept. This direct activation occurred regardless of HLA-B*58:01 status. Although most OXP-specific T cells from HLA-B*58:01(+) donors were restricted by the HLA-B*58:01 molecule for drug recognition, ALP-specific T cells also were restricted to other MHC class I molecules. This can be explained by in silico docking data that suggest that OXP binds to the peptide-binding groove of HLA-B*58:01 with higher affinity. The ensuing T cell responses elicited by ALP or OXP were not limited to particular TCR Vβ repertoires. We conclude that the drug-specific T cells are activated by OXP bound to HLA-B*58:01 through the p-i mechanism.